Physician profile
David Starnes
NPI 1851470231
$2,181.27
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,141 · 2022: $896 · 2023: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $144.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.92 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.93 | 2021-2022 | |
| Pfizer INC. | $285.38 | 2021-2022 | |
| Lilly USA, LLC | $183.25 | 2021-2022 | |
| Glaxosmithkline, LLC. | $166.91 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $93.88 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.99 | 2021-2022 | |
| Novo Nordisk INC | $79.78 | 2021-2022 | |
| Antares Pharma, INC. | $75.26 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $41.13 | 2021-2022 | |
| Abbott Laboratories | $40.09 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $38.79 | 2021 | |
| Eisai INC. | $34.40 | 2021-2022 | |
| Biogen, INC. | $31.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.40 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.72 | 2021 | |
| Xeris Pharmaceuticals, INC. | $28.11 | 2022 | |
| Boston Scientific Corporation | $19.67 | 2022 | |
| Acadia Pharmaceuticals INC | $17.83 | 2022 | |
| Mylan Specialty L.P. | $17.02 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.70 | 2022 | |
| Lundbeck LLC | $16.09 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.85 | 2022 | |
| Almatica Pharma LLC | $15.60 | 2021 | |
| Dexcom, INC. | $14.45 | 2022 | |
| Sumitomo Pharma America, INC. | $14.00 | 2023 | Gemtesa |
| Radius Health, INC. | $13.72 | 2021 | |
| Genentech USA, INC. | $9.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Starnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.